Charles River Labs Intl (CRL-N)
NYSE:CRL
105.92
0.68
(0.64%) 1d
Financials
Technical Analysis
This summary was created by AI, based on 1 opinions in the last 12 months.
Charles River Labs Intl (CRL) is a robust company specializing in drug discovery and safety testing services, currently trading at a forward P/E ratio of 22.6, which falls within the historical range of 19x to 33x. Over the past five years, the company has demonstrated healthy revenue growth, averaging around 12%, primarily driven by strategic acquisitions. Despite carrying a slightly leveraged balance sheet with net debt at $2.8 billion and a net debt/EBITDA ratio of 2.7x, Charles River has managed to generate strong cash flow while repurchasing shares. While the consensus estimates predict a modest 2% sales growth for this year, a normalization to around 7% is expected in the following years, reinforcing the company's potential for future growth. Overall, experts view CRL as a solid investment opportunity with strong fundamentals and healthy cash generation, although the stock is considered slightly expensive relative to its high-quality business profile.
- «
- ‹
- 1
- ›
- »
Charles River Labs Intl(CRL-N) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 1
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 1
Charles River Labs Intl(CRL-N) Frequently Asked Questions
What is Charles River Labs Intl stock symbol?
Charles River Labs Intl is a American stock, trading under the symbol CRL-N on the New York Stock Exchange (CRL). It is usually referred to as NYSE:CRL or CRL-N
Is Charles River Labs Intl a buy or a sell?
In the last year, 1 stock analyst published opinions about CRL-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Charles River Labs Intl.
Is Charles River Labs Intl a good investment or a top pick?
Charles River Labs Intl was recommended as a Top Pick by on . Read the latest stock experts ratings for Charles River Labs Intl.
Why is Charles River Labs Intl stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Charles River Labs Intl worth watching?
1 stock analyst on Stockchase covered Charles River Labs Intl In the last year. It is a trending stock that is worth watching.
What is Charles River Labs Intl stock price?
On 2025-04-15, Charles River Labs Intl (CRL-N) stock closed at a price of $105.92.
CRL provides drug discovery and safety testing services and is now trading at 22.6 times' Forward P/E (historical averages range from 19x to 33x). In the last five years, revenue growth was quite healthy, averaging around 12% on average, largely driven through acquisitions. The balance sheet is slightly leveraged, with net debt of $2.8B and net debt/EBITDA of around 2.7x. The company has been growing and repurchasing shares over the last few years. It is a solid company in our view, but as might be expected the valuation is a little expensive given the high quality of the business (not excessive though at 22X earnings). Based on consensus estimates, sales are expected to grow by 2% this year and then normalize to around 7% over the next few years. Overall, an interesting name with strong growth and healthy cash generation. We would be comfortable owning it.
Unlock Premium - Try 5i Free